+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Hip Reconstruction Market Outlook to 2025

  • PDF Icon

    Report

  • 104 Pages
  • June 2018
  • Region: United States
  • GlobalData
  • ID: 4580311
United States Hip Reconstruction Market Outlook to 2025

Summary

This new report, United States Hip Reconstruction Market Outlook to 2025, provides key market data on the United States Hip Reconstruction market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market categories - Hip Resurfacing, Partial Hip Replacement, Primary Hip Replacement and Revision Hip Replacement.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope
  • Market size and company share data for Hip Reconstruction market categories - Hip Resurfacing, Partial Hip Replacement, Primary Hip Replacement and Revision Hip Replacement.

  • Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2015 to 2025.

  • 2017 company share and distribution share data for Hip Reconstruction market.

  • Global corporate-level profiles of key companies operating within the United States Hip Reconstruction market.

  • Key players covered include Stryker Corp, Zimmer Biomet Holdings Inc, DePuy Synthes Inc and Others.


Reasons to buy
  • Develop business strategies by identifying the key market categories poised for strong growth in the future.

  • Develop market-entry and market expansion strategies.

  • Design competition strategies by identifying who-stands-where in the market.

  • Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.

  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Hip Reconstruction Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Hip Reconstruction Market, United States
3.1 Hip Reconstruction Market, United States, Revenue ($m), 2015-2025
3.1.1 Partial Hip Replacement Market, United States, Revenue ($m), by Segment, 2015-2025
3.1.2 Primary Hip Replacement Market, United States, Revenue ($m), by Segment, 2015-2025
3.2 Hip Reconstruction Market, United States, Volume (Units), 2015-2025
3.2.1 Partial Hip Replacement Market, United States, Volume (Units), by Segment, 2015-2025
3.2.2 Primary Hip Replacement Market, United States, Volume (Units), by Segment, 2015-2025
3.3 Hip Reconstruction Market, United States, Average Price ($), 2015-2025
3.4 Hip Reconstruction Market, United States, Distribution Share by Revenue ($m), 2017
3.5 Hip Reconstruction Market, United States, Company Share by Revenue ($m), 2017
4 Overview of Key Companies in United States, Hip Reconstruction Market
4.1 Zimmer Biomet Holdings Inc
4.1.1 Company Overview
4.2 DePuy Synthes Inc
4.2.1 Company Overview
4.3 Stryker Corp
4.3.1 Company Overview
4.4 Exactech Inc
4.4.1 Company Overview
4.5 Smith & Nephew Plc
4.5.1 Company Overview
4.6 MicroPort Orthopedics Inc
4.6.1 Company Overview
5 Hip Reconstruction Market Pipeline Products
6 Financial Deals Landscape
6.1 Debt Offerings
6.1.1 Zimmer Biomet Raises USD450 Million in Public Offering of Notes Due 2021
6.2 Equity Offerings
6.2.1 Amedica Files Registration Statement for Rights Offering of Units for up to USD11.4 Million
6.3 Private Equity
6.3.1 TPG Capital Amends Agreement to Acquire Exactech
6.3.2 JANA Partners Denies Rumor to Acquire Certain Stake in Zimmer Biomet
6.4 Venture Financing
6.4.1 Active Implants Raises USD3.3 Million in Venture Financing
6.4.2 OrthAlign Raises USD7.6 Million in Financing
7 Recent Developments
7.1 Corporate Communications
7.1.1 May 14, 2018: OMNIlife science Appoints Rick Epstein as Chief Executive Officer
7.1.2 Apr 30, 2018: HSS Surgeon Michael L. Parks, MD, Named President of Orthopaedic Research and Education Foundation
7.1.3 Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory
7.1.4 Mar 19, 2018: Zimmer Biomet Appoints Coleman N. Lannum as Senior Vice President of Investor Relations
7.1.5 Mar 13, 2018: Orthofix Announces Appointment of John Sicard to Board of Directors
7.1.6 Mar 05, 2018: Henry Ford Health System Appoints Adnan Munkarah As New Executive Vice President & Chief Clinical Officer
7.1.7 Mar 05, 2018: Orthopaedic Industry Veteran Jeffrey R. Binder Joins Bill Petty, MD, as Co-Executive Chairman of Exactech; Daniel Hann Joins Exactech as Sr. Vice President of Business Development
7.1.8 Feb 20, 2018: Onconova Announces Presentation on its Acute Myeloid Leukemia Drug Candidate ON-150030 at 2018 American Chemical Society National Meeting and Expo
7.1.9 Dec 19, 2017: Zimmer Biomet Announces Appointment of Bryan C. Hanson as President and Chief Executive Officer
7.1.10 Dec 12, 2017: Stryker announces Mr. Howard E. Cox, Jr. will retire from Board of Directors
7.1.11 Dec 08, 2017: Henry Ford Cardiologist Named to American College of Cardiology Executive Leadership
7.1.12 Sep 26, 2017: Pharming Group and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for “HAEi Global Access Program”
7.1.13 Sep 06, 2017: GE Healthcare: Untangling the wires using MRI research to help understand the brain
7.1.14 Aug 23, 2017: Henry Ford Hospital CEO Announces Retirement
7.1.15 Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd
7.1.16 Jul 19, 2017: Mr. Stephen Ooi, Former Zimmer Executive, Newly Appointed as Independent Board Director of XinRong Medical
7.1.17 Jul 11, 2017: Zimmer Biomet Announces Leadership Transition
7.1.18 Jun 26, 2017: Henry Ford Welcomes Three New Senior Executives
7.2 Financial Announcements
7.2.1 Apr 30, 2018: Orthofix Announces First Quarter 2018 Financial Results
7.2.2 Apr 26, 2018: Zimmer Biomet Reports First Quarter 2018 Financial Results
7.2.3 Apr 26, 2018: Stryker reports first quarter 2018 operating results
7.2.4 Feb 26, 2018: Orthofix International Reports Fourth Quarter And Fiscal 2017 Financial Results
7.2.5 Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities
7.2.6 Jan 30, 2018: Zimmer Biomet Announces Fourth Quarter and Full-Year 2017 Results
7.2.7 Jan 30, 2018: Stryker reports 2017 results and 2018 outlook
7.2.8 Jan 09, 2018: Stryker provides 2017 preliminary net sales results
7.2.9 Jan 09, 2018: Orthofix Announces Preliminary 2017 Fourth Quarter and Full Year Net Sales Results
7.2.10 Nov 01, 2017: Zimmer Biomet Reports Third Quarter 2017 Financial Results
7.2.11 Oct 30, 2017: Orthofix International Reports Third Quarter 2017 Financial Results
7.2.12 Oct 30, 2017: Exactech Q3 Revenue $61.4 Million
7.2.13 Oct 26, 2017: Stryker reports third quarter 2017 results
7.2.14 Oct 06, 2017: Bruker Introduces Fungiplex Candida Assay into European Clinical Microbiology Markets
7.2.15 Oct 06, 2017: Integra LifeSciences launches Revize Collagen Matrix for Plastic and Reconstructive Surgery
7.2.16 Sep 26, 2017: Psychemedics Announces Addition of FDA-Cleared Benzodiazepines Hair Test
7.2.17 Sep 26, 2017: Moleculin Announces FDA Approval of Annamycin IND
7.2.18 Sep 22, 2017: Amedica Releases First and Second Quarter 2017 Preliminary Unaudited Earnings Report and Business Update
7.2.19 Sep 07, 2017: MannKind Responds to Hurricane Harvey Devastation with Afrezza Donation
7.2.20 Aug 07, 2017: Orthofix International Reports Second Quarter 2017 Financial Results
7.2.21 Jul 27, 2017: Zimmer Biomet Reports Second Quarter 2017 Financial Results
7.2.22 Jul 27, 2017: Stryker reports second quarter 2017 results
7.2.23 Jul 27, 2017: Exactech Q2 Revenue $67.3 Million On Continuing Strong Extremities Revenue
7.2.24 Jul 11, 2017: Zimmer Biomet Reports Certain Preliminary Second Quarter 2017 Results
7.2.25 Jun 20, 2017: IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of
7.2.26 Jun 08, 2017: Amedica Releases 2016 Preliminary Earnings Report and Business Update
7.2.27 Jun 03, 2017: Longer Term Follow-Up Data with Mercks KEYTRUDA (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting
7.3 Government and Public Interest
7.3.1 Mar 09, 2018: HSS Study Finds Consensus Needed for Joint Replacement Performance Measurement
7.3.2 Aug 29, 2017: ivWatch Awarded New Innovative Technology Contract From Vizient
7.4 Legal And Regulatory
7.4.1 May 16, 2018: Zimmer Biomet Statement on Warsaw North Campus FDA Inspection
7.4.2 Apr 12, 2018: Sonova Showcases Expanded Product Portfolio at AAA 2018
7.4.3 Feb 22, 2018: GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU
7.4.4 Dec 01, 2017: Amedica Receives Positive Nasdaq Listing Decision
7.4.5 Aug 30, 2017: Medovex Corporation to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
7.4.6 Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker
7.4.7 Jun 14, 2017: Glenmark Pharmaceuticals receives tentative ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg
7.4.8 Jun 13, 2017: Zimmer Biomet Holdings Announces Resolution of FDA Warning Letter Related to Its Zhejiang, China Manufacturing Facility
7.4.9 May 30, 2017: CSA Medical Announces Expansion of truFreeze Label to Include Barrett's Esophagus with High Grade Dysplasia
7.5 Other Significant Developments
7.5.1 Mar 08, 2018: Geisinger Announces It Will Stand Behind Cost of Hip Surgery for a Lifetime
7.5.2 Dec 06, 2017: Advanced, Minimally Invasive Hip and Knee Replacement Procedures Offered at Wilcox Medical Center
7.5.3 Nov 21, 2017: Littleton Adventist to offer robotic technology for knee replacements
7.5.4 Nov 02, 2017: ZS-9 (sodium zirconium cyclosilicate) Phase III long-term safety and efficacy data presented at ASN Kidney Week 2017
7.5.5 Oct 04, 2017: Zimmer Biomet Provides Update on Manufacturing Facilities in Guaynabo and Ponce, Puerto Rico
7.5.6 Sep 26, 2017: Cytex receives 4 new federal grants
7.6 Product News
7.6.1 Apr 19, 2018: Corail Hip System Collared Femoral Stem Demonstrates a 29% Lower Revision Risk Compared to Class, According to Independent Joint Registry Data
7.6.2 Mar 06, 2018: Exactech Knee System, Ankle, Shoulder Stem, Hip Stem and Computer-Assisted Surgery Technology Headline at Booth 5023, AAOS 2018 Annual Meeting
7.6.3 Mar 06, 2018: New Assessment Tool Helps Identify Risk for Post-Surgical Dislocations Following Total Hip Replacement
7.6.4 Mar 06, 2018: Neurocognitive Impairment Linked to Worse Outcomes After Total Joint Replacement
7.6.5 Jan 08, 2018: MicroPort Orthopedics Attends 12th COA
7.6.6 Nov 27, 2017: OrthoPediatrics to Highlight its Products at the 14th Annual International Pediatric Orthopaedic Symposium
7.6.7 Aug 11, 2017: Bonovo participated in the Chinese Medical Association of neurosurgery branch of the 16th academic conference
7.6.8 Aug 05, 2017: Bonovo participated in the first session of the Great Wall Orthopedic Forum, the 14th Beijing Orthopedic Association (BOA) and the first Beijing - Shanghai Orthopedic Summit meeting
7.6.9 Jun 22, 2017: Exactech Expands Presence in Japan with Newly Approved Shoulder, Knee and Hip Replacement Systems
7.6.10 May 31, 2017: Depuy Synthes and Ethicon to Showcase Intra Operative Solutions Aiming to Mitigate Surgical Site Infection During Efort Congress
7.7 Strategy And Business Planning
7.7.1 Dec 11, 2017: Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
8 Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 Consulting
8.3 Contact Us
8.4 Disclaimer
List of Tables
Table 1: Hip Reconstruction Market, United States, Revenue ($m), USD Constant, 2015-2020
Table 2: Hip Reconstruction Market, United States, Revenue ($m), USD Constant, 2021-2025
Table 3: Partial Hip Replacement Market, United States, Revenue ($m), USD Constant, 2015-2020
Table 4: Partial Hip Replacement Market, United States, Revenue ($m), USD Constant, 2021-2025
Table 5: Primary Hip Replacement Market, United States, Revenue ($m), USD Constant, 2015-2020
Table 6: Primary Hip Replacement Market, United States, Revenue ($m), USD Constant, 2021-2025
Table 7: Hip Reconstruction Market, United States, Volume (Units), 2015-2020
Table 8: Hip Reconstruction Market, United States, Volume (Units), 2021-2025
Table 9: Partial Hip Replacement Market, United States, Volume (Units), 2015-2020
Table 10: Partial Hip Replacement Market, United States, Volume (Units), 2021-2025
Table 11: Primary Hip Replacement Market, United States, Volume (Units), 2015-2020
Table 12: Primary Hip Replacement Market, United States, Volume (Units), 2021-2025
Table 13: Hip Reconstruction Market, United States, Average Price ($), 2015-2020
Table 14: Hip Reconstruction Market, United States, Average Price ($), 2021-2025
Table 15: Hip Reconstruction Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017
Table 16: Hip Reconstruction Market, United States, Company Share by Revenue ($m), USD Constant, 2017
Table 17: Hip Reconstruction Market Pipeline Products
Table 18: Zimmer Biomet Raises USD450 Million in Public Offering of Notes Due 2021
Table 19: Amedica Files Registration Statement for Rights Offering of Units for up to USD11.4 Million
Table 20: TPG Capital Amends Agreement to Acquire Exactech
Table 21: JANA Partners Denies Rumor to Acquire Certain Stake in Zimmer Biomet
Table 22: Active Implants Raises USD3.3 Million in Venture Financing
Table 23: OrthAlign Raises USD7.6 Million in Financing
Table 24: Total Number of Primary Research Participants, Orthopedic Devices Market, by Country
List of Figures
Figure 1: Hip Reconstruction Market, United States, Revenue ($m), USD Constant, 2015-2025
Figure 2: Partial Hip Replacement Market, United States, Revenue ($m), USD Constant, 2015-2025
Figure 3: Primary Hip Replacement Market, United States, Revenue ($m), USD Constant, 2015-2025
Figure 4: Hip Reconstruction Market, United States, Volume (Units), 2015-2025
Figure 5: Partial Hip Replacement Market, United States, Volume (Units), 2015-2025
Figure 6: Primary Hip Replacement Market, United States, Volume (Units), 2015-2025
Figure 7: Hip Reconstruction Market, United States, Company Share (%) 2017

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Zimmer Biomet Holdings Inc

  • DePuy Synthes Inc

  • Stryker Corp

  • Exactech Inc

  • Smith & Nephew Plc

  • MicroPort Orthopedics Inc